Prothena | PRTA - Assets


Prothena reported $349.89M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Akebia Therapeutics USD 362.52M 14.04M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Exelixis USD 2.59B 250.83M Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Prothena USD 349.89M 23.09M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xoma USD 263.15M 39.7M Sep/2025